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ARTICLE OPEN
N-methyl-D-aspartate receptor availability in first-episode
psychosis: a PET-MR brain imaging study
Katherine Beck 1,2,3,4✉, Atheeshaan Arumuham1,2,3,4, Mattia Veronese 1,5, Barbara Santangelo1,5, Colm J. McGinnity6, Joel Dunn 6,
Robert A. McCutcheon 1,2,3,4, Stephen J. Kaar1,2,3,4, Nisha Singh5, Toby Pillinger 1,2,3,4, Faith Borgan 1,8, James Stone 1,3,5,7,
Sameer Jauhar 1,2,3,4, Teresa Sementa6, Federico Turkheimer 5, Alexander Hammers6 and Oliver D. Howes1,2,3,4✉
© The Author(s) 2021
N-methyl-D-aspartate receptor (NMDAR) hypofunction is hypothesised to underlie psychosis but this has not been tested early in
illness. To address this, we studied 40 volunteers (21 patients with first-episode psychosis and 19 matched healthy controls) using
PET imaging with an NMDAR selective ligand, [18F]GE-179, that binds to the ketamine binding site to index its distribution volume
ratio (DVR) and volume of distribution (VT). Hippocampal DVR, but not VT, was significantly lower in patients relative to controls
(p= 0.02, Cohen’s d= 0.81; p= 0.15, Cohen’s d= 0.49), and negatively associated with total (rho=−0.47, p= 0.04), depressive
(rho=−0.67, p= 0.002), and general symptom severity (rho=−0.74, p < 0.001). Exploratory analyses found no significant
differences in other brain regions (anterior cingulate cortex, thalamus, striatum and temporal cortex). These findings are consistent
with the NMDAR hypofunction hypothesis and identify the hippocampus as a key locus for relative NMDAR hypofunction, although
further studies should test specificity and causality.
Translational Psychiatry          (2021) 11:425 ; https://doi.org/10.1038/s41398-021-01540-2
INTRODUCTION
Schizophrenia is a chronic mental illness with a lifetime prevalence
of 1% [1]. It has been ranked the third most disabling illness
worldwide [2]. Several lines of evidence indicate that the
pathophysiology of schizophrenia and related psychotic disorders
involves N-methyl-D-aspartate receptor (NMDAR) hypofunction
[3–7]. This hypothesis was initially proposed in the 1990s [8, 9] on
the basis of observations that ketamine and phencyclidine (PCP)
induced the full range of schizophrenia-like symptoms (positive,
negative and cognitive) when given to healthy participants; and
evidence that these compounds worsen symptoms in patients
with schizophrenia [10–12]. Ketamine and PCP show uncompeti-
tive NMDAR antagonism through binding to an intrachannel
binding site to block the active channel [13].
Genome-wide association studies have identified genetic
variants related to the structure and function of the NMDAR that
are associated with schizophrenia, including GRIN2A and serine
racemase (SRR) [14]. Mice with reduced NMDAR expression display
schizophrenia-like phenotypes [15–17]. There is also evidence
from post-mortem studies that the NMDAR density is reduced in
the hippocampus of humans with schizophrenia [18]. While these
studies indicate the NMDAR is altered in schizophrenia, the only
in vivo imaging study of the NMDAR in schizophrenia to date used
[123I]CNS-1261, a single-photon emission tomography (SPECT)
radioligand, selective for the intrachannel ketamine/PCP binding
site [19, 20]. This study found a lower ratio of tracer binding in the
left hippocampus to that in the whole brain in antipsychotic-free
patients relative to healthy participants. Moreover, the hippocam-
pal binding ratio was negatively correlated with total and negative
symptom severity in antipsychotic-treated patients. However, as
the study was conducted in chronic patients, it is unknown if
NMDAR alterations are present early in the illness or if they may be
secondary to the effects of illness chronicity.
In view of this, we investigated the in vivo availability of NMDAR
in patients with first-episode psychosis (FEP). We hypothesized
that patients would show lower NMDAR availability in the
hippocampus relative to matched healthy controls; and that
NMDAR availability would be negatively correlated with symptom
severity. In addition, as NMDAR availability has been found to be
reduced in patients with epilepsy receiving antidepressants for
depressive symptoms [21], we tested whether there was an
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capacity and provided written informed consent to participate. We
followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guidelines for case-control studies.
Participants
Data were collected from November 7, 2016 until August 2, 2019. Patients
were recruited from FEP services in London, United Kingdom. Inclusion
criteria were as follows: a diagnosis of a DSM-IV psychotic disorder
according to the Structured Clinical Interview of DSM-IV-TR Axis I Disorders-
Patient Edition [22], fulfilling criteria for having the first episode of
psychosis [23], and less than 5 years’ illness duration. For comparison, a
sample of healthy controls matched on age (+/−3 years) and sex were
included. Inclusion criteria were as follows: no current or lifetime history of
Axis I Disorder as determined by the Structural Clinical Interview of DSM-IV-
TR Axis I Disorders-Patient Edition [22].
Exclusion criteria for all volunteers were as follows: history of significant
head trauma (such as loss of consciousness >1min or requiring hospital
admission), dependence on illicit substances or alcohol, positive urine drug
test (SureScreen Diagnostics, Derby, UK) for any illicit substances that
might affect NMDAR (e.g. stimulants) on the day of scanning, medical
comorbidity (other than minor illnesses), current use (no use within
3 months) of any of the following drugs which may interfere with NMDAR;
antidepressants [21], mood stabilizers [24–26], benzodiazapines [27]; and
contraindications to scanning (such as pregnancy) (see eMethods 1 in the
Supplement for full exclusion criteria).
Medication status. Participants with psychosis were classified as
antipsychotic-free if they had been free from antipsychotic treatment for
at least 6 weeks for oral or 6 months for depot formulations [28].
Antipsychotic-naive was defined as having had no antipsychotic treatment
at all.
In total n= 32 patients were screened for eligibility, n= 25 were
deemed eligible, and n= 21 were included in the study. N= 36 healthy
volunteers were screened for eligibility as controls, n= 34 were deemed
eligible, and n= 19 were included in the study. Participants who were
deemed eligible, but were not included in the study, withdrew following
screening prior to scanning.
The final sample included n= 40 individuals, including n= 19 healthy
controls and n= 21 patients (n= 12 antipsychotic-free and n= 9 treated
with antipsychotics).
Measures
Clinical and demographic variables. Current age and illness duration were
recorded. Clinical symptom severity was determined using the Positive and
Negative Syndrome Scale (PANSS) [29]. Psychotropic medication histories
were recorded, urine drug screens were performed, and equivalent
chlorpromazine doses were calculated using the method reported by
Leucht et al. [30].
Neuroimaging
All participants underwent a dynamic, continuous 90-min simultaneous
PET-MR acquisition after a bolus injection of [18F]GE-179 (mean [SD], 140.31
[9.04] MBq) with a Siemens 3T Biograph mMR PET/MR hybrid scanner
(Siemens, Erlangen, Germany). In parallel to PET/MR imaging, continuous
arterial sampling using an MR compatible blood sampler (http://www.
swisstrace.ch/blood-sampler-twilite.html) was performed for the first
16min followed by 6 discrete samples (see eMethods 2 in the Supplement
for the full acquisition protocol). A T1-weighted structural Magnetization
Prepared Rapid Gradient-Echo (MP-RAGE) image was acquired for co-
registration (see eMethods 3 in the Supplement for the sequences). At the
end of the session, a separate low dose CT scan (140 kV, 10 mA, helical
acquisition) of the subject’s head was acquired on a GE Discovery DST 710
PET/CT (GE Healthcare, Chicago, Illinois, USA), and used for tissue
attenuation correction during the PET image reconstruction. This
additional CT scan was required because, at the time of the study starting,
MRI based methods for attenuation correction had not been validated.
The person conducting the image analysis was blinded to the group
status of the volunteers. NMDAR availability was determined as the [18F]
GE-179 volume of distribution (VT, mL/cm
3) calculated using the standard
2-tissue compartmental modelling method with a metabolite-corrected
arterial plasma input function, consistent with previous [18F]GE-179 brain
PET studies [31] (see eMethods 4–9 in the Supplement for more
information on PET image analysis and model validation). Prior to kinetic
modelling, all the individual PET data underwent the same image
processing pipeline to measure and correct for subject motion, segment
brain tissues and extract [18F]GE-179 tracer activity in the main regions of
interest. For comparison with previous results [19], PET analysis was
performed using the distribution volume ratio (DVR), calculated for the
aforementioned regions as follows: region of interest VT/VT. The
hippocampus was the primary region of interest given the prior findings
of Pilowsky et al. [19] and evidence implicating it in the pathophysiology
of psychotic and cognitive symptoms [18, 32, 33]. Exploratory analyses
were conducted in the following additional ROIs: the anterior cingulate
cortex (ACC), thalamus, striatum, and temporal lobe. These regions were
chosen because prior studies have shown that patients with schizophrenia
show glutamatergic dysfunction in these regions [18, 34]. Further
exploratory analyses were completed to compare hippocampal DVR and
VT across subgroups (antipsychotic-free patients, antipsychotic-treated
patients and healthy controls). To determine if volumetric group
differences influenced our findings, hippocampal volumes were compared
across groups (eMethod 7).
Exploratory voxel-wise analyses were also conducted to determine if
there were alterations in brain regions outside of the regions of interest
using [18F]GE-179 VT parametric maps derived using the Logan graphical
approach [35]. The main outputs from the image analysis were manually
quality controlled (QC) by an experienced PET modeller (MV), blinded to
subject status (for full description see eMethods 4 PET image analysis in
the Supplement). Participants were excluded on the basis that there were
still obvious artefacts on the motion corrected images and TACs (e.g. frame
misalignment and signal drops in particular frames (for full description see
eMethods 4 PET image analysis in the Supplement). Scans which failed QC
were not included in the statistical analysis.
Statistical analysis
Statistical Product and Service Solutions (SPSS) version 22 (IBM Corp) was
used for all statistical analyses and the significance level was set to p < 0.05
(two-tailed). Data normality was assessed using the Shapiro–Wilk test.
Categorical clinical, demographics, and experimental variables were
compared across groups using χ2 tests; and continuous variables were
assessed using independent samples t-tests and Mann–Whitney tests for
parametric and non-parametric data, respectively.
To determine whether hippocampal tracer uptake was lower in patients as
compared to controls, an independent samples t-test was used.
Mann–Whitney tests were used to analyze DVR data as they were non-
normally distributed. To explore if there were effects in other regions,
independent t-tests and Mann–Whitney tests were again used to identify if
other areas known to be involved in schizophrenia had different tracer
uptake. Independent t-tests and Mann–Whitney tests were also used for
exploratory analyses to compare hippocampal DVR and VT across subgroups
(antipsychotic-free patients, antipsychotic-treated patients and healthy
controls) and to compare hippocampal volumes between the patient and
healthy control groups. None of the exploratory analyses (additional ROIs or
patient subgroup analyses) were corrected for multiple comparisons as they
were exploratory. Effect sizes were summarised as Cohen’s d, and calculated
using the difference in means between groups and the pooled standard
deviation of the patient and control groups. The coefficient of variation was
calculated for the VT and DVR of the hippocampus and other exploratory
regions, in both patient and control groups, by calculating the ratio of the
standard deviation to the mean (see eTable 1).
To investigate our hypothesis that tracer uptake was negatively
associated with symptom severity, Pearson’s or Spearman’s correlation
coefficients were calculated for normally and non-normally distributed
data respectively, including PANSS total symptom severity as the
independent variable, and tracer DVR or VT as the dependent variables.
We also performed secondary analyses to explore if there were
relationships with the general, positive, and negative subscales, using
Bonferroni corrections to adjust for multiple comparisons in these
exploratory analyses. We used the same approach to test our
exploratory hypothesis that NMDAR availability would be negatively
associated with depressive symptoms, using the score on the
depressive item of the PANSS. Spearman’s correlation coefficients were
calculated to determine if there were associations between hippocam-
pal DVR and antipsychotic dose and hippocampal volume [36]. To
further determine whether volume effects affected the results we
performed a one-way ANOVA with hippocampal DVR as the dependent
variable and group (patient or control) as the independent variables
with hippocampal volume as the covariate.
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Demographics and experimental variables
A total of n= 40 individuals participated in the study, including
n= 19 healthy controls and n= 21 patients (n= 12 antipsychotic-
free and n= 9 treated with antipsychotics). One healthy control
was excluded due to a malfunction of the arterial line, and two
patients were excluded due to a positive urine test for cocaine
(n= 1), or QC failure (n= 1). A total of n= 37 individuals (n= 18
healthy controls and n= 19 patients, of whom n= 11 were
antipsychotic-free) were included in the final analysis.
No significant group differences were found for age (t35= 0.93,
p= 0.36) (Table 1), hippocampal, or whole-brain tissue volume
(see eTable 1 and eResults 1 in the Supplement), cumulative
movement, input function, injected mass, injected activity, or
molar activity (see eTable 2 in the Supplement).
Tracer uptake in hippocampus
The hippocampal DVR data were not normally distributed (p < 0.03).
Hippocampal DVR was significantly lower in the patient sample
(Mean Rank= 14.84) compared to healthy controls (Mean Rank=
23.39; Mann–Witney test: U= 92.00; z=−2.40, p= 0.02; Cohen’s d=
0.81; Fig. 1). The coefficients of variation in hippocampal DVR for the
patient and control groups were 7.5% and 7.1%, respectively. We
conducted sensitivity analyses to determine if hippocampal volume
could influence our findings. These showed that there was no
correlation between hippocampal volume and hippocampal DVR
(rho −0.14, p= 0.4), and there was still a significant effect of group
on hippocampal DVR when hippocampal volume was included as a
covariate (F(1,34)= 5.8, p= 0.02).
When antipsychotic-free patients were compared with healthy
controls, there was no significant difference in hippocampal DVR
(Mann–Witney test: U= 68.00; z=−1.39 p= 0.17; eFigure 1
in Supplementary Material). However, hippocampal DVR was
significantly lower in the patient group taking antipsychotics
relative to healthy controls Mann–Witney test: U= 24.00; z=
−2.67, p= 0.006; eFigure 1 in Supplementary Material). There was
no significant difference between antipsychotic-free and treated
patient groups (Mann–Witney test: U= 24.00; z=−1.65 p= 0.10;
eFigure 1 in Supplementary Material). Furthermore, there was no
significant correlation between antipsychotic dose and hippo-
campal DVR (rho=−0.16, p= 0.71).
Volume of distribution data were normally distributed (p=
0.63). While in absolute terms hippocampal VT was lower in the
patient group (Cohen’s d= 0.49), there was no statistically
significant effect of group on VT in the hippocampus (t35= 1.49,
p= 0.15; Fig. 1). The coefficients of variation in VT for the patient
and control groups were 22.7% and 18.2%, respectively. There
were no significant differences in the comparisons between
patients subgrouped on the basis of antipsychotic treatment and
controls (antipsychotic-free vs healthy controls (t27=−0.75, p=
0.46; eFigure 2 in Supplementary Material), antipsychotic-treated
vs healthy controls (t24=−1.94, p= 0.06; eFigure 2 in Supplemen-
tary Material), antipsychotic-free vs antipsychotic-treated (t17=
0.94,
p= 0.36; eFigure 2 in Supplementary Material).
Tracer uptake in additional brain areas and whole brain
Figure 2 shows mean parametric maps of VT of [
18F]GE-179 for
controls and patients, showing widespread uptake of the tracer
throughout grey matter, in line with the expected distribution of
NMDAR [31]. There was no significant effect of group on VT or DVR
of [18F]GE-179 when investigated in the exploratory ROIs (the ACC,
thalamus, striatum or temporal lobe; see eTable 1 and eResults 2
in the Supplement). Similarly, the voxel-wise analysis did not
identify significant group differences in the VT of [
18F]GE-179 in
the hippocampus or other brain regions between patients and
controls (see eResults 3 in the Supplement). There was no
significant effect of group on VT in the whole brain (t35= 0.60,
p= 0.56, Cohen’s d= 0.20).
NMDAR availability and symptoms
There was a significant negative association between PANSS total
symptom severity and hippocampal DVR (rho=−0.47, p= 0.04;
Fig. 3). In addition, there was a significant negative association
between hippocampal DVR and PANSS general symptom severity
(rho=−0.74, p < 0.001; Fig. 4), but not with positive (rho=−0.41,
p= 0.08), or negative (rho= 0.35, p= 0.14) symptom severity.
Hippocampal DVR was also negatively associated with the
depression item of the PANSS scale (rho=−0.67, p= 0.002;
Fig. 5). The negative correlation between both general symptom
severity and depression item with hippocampal DVR survived
Bonferroni correction (αcorrected= 0.05/5= 0.01).
The association between hippocampal VT, and PANSS scores,
was assessed using Pearson’s correlation. The relationship
between VT and total PANSS was not significant (r=−0.43,
p= 0.06; eFigure 3 in Supplementary Material), along with positive
Table 1. Clinical and demographic variables.
Characteristic Healthy volunteers (n= 18) Patients with FEP (n= 19)
Age, years, mean (SD) 26.7 (4.5) 25.3 (4.9)
Sex, No. male/female 14/4 15/4
Diagnosis, schizophrenia (n)/schizoaffective disorder (n) 19/0
Illness duration, months, mean (SD) 23 (16.5)
Antipsychotic-free/naive (n) 8/3
For patients taking antipsychotic treatment; chlorpromazine equivalent dose (mg/d),
mean (SD)
393 (166)
Current antipsychotic medication (n): Aripiprazole:Apripirazole&Olanzapine:
Risperidone:Lurasidone
4:1:2:1
PANSS positive score, mean (SD)a 19.2 (4.4)
PANSS negative score, mean (SD)a 19.6 (5.7)
PANSS general score, mean (SD)a 36.6 (7.3)
PANSS total score, mean (SD)a 75.4 (11.1)
PANSS depression item of rating, mean (SD) 2.4 (1.5)
FEP first-episode psychosis, Shaded box not applicable, PANSS Positive and Negative Syndrome Scale, SD standard deviation, n number.
aScores range for total PANSS: 53–88, general PANSS subscale: 25–46, positive subscale of the PANSS: 12–27; negative subscale of the PANSS: 8–28; and
depression item: 1–6. Higher scores indicate greater symptom severity.
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PANSS (r=−0.30, p= 0.21), and negative PANSS (r= 0.08, p=
0.76). However, there was a significant negative correlation
between hippocampal VT and general PANSS (r=−0.53, p=
0.02, eFigure 4 in Supplementary Material), and the depression
item of the PANSS (r=−0.56, p= 0.01, eFigure5 in Supplementary
Material).
DISCUSSION
We found a significantly lower DVR of the NMDAR selective
radiotracer, [18F]GE-179, in the hippocampus in patients with
schizophrenia compared to healthy controls. In absolute terms,
the hippocampal VT values of [
18F]GE-179 were also lower in
schizophrenia compared to controls, but this difference was not

























A    [18F] GE179 PET imaging DVR measure B    [18F] GE179 PET imaging VT measure
0 0
Fig. 1 [18F]GE-179 DVR and VT hippocampus. NMDAR availability measured by positron emission tomographic (PET) imaging was
significantly lower in the hippocampus in patients with first-episode psychosis when DVR was measured (A) but not when VT was measured






Fig. 2 [18F]GE-179 VT. There was no significant difference in
NMDAR availability in the hippocampus between patients and
controls t35= 1.49, p= 0.15 as determined by the distribution
volume (VT; measured in millilitres per cubic centimetre). Images
are mean parametric maps for controls (A), sample (B).
















rho = - 0.47, p = 0.043
Fig. 3 Relationship of tracer uptake in the hippocampus, as
measured by DVR, and total PANSS symptom severity. Dashed line
represents 95% CI.













rho = - 0.74, p < 0.001
Fig. 4 Relationship of tracer uptake in the hippocampus, as
measured by DVR, and General PANSS symptom severity. Dashed
line represents 95% CI.
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variability seen with DVR (coefficients of variation for the
hippocampus in healthy controls were 18.2% and 7.1%, respec-
tively). Thus, the greater noise in the VT measure may have
contributed to the lack of a significant difference in this measure
in the hippocampus compared to the DVR.
This is the first in vivo study using an NMDAR selective
radiotracer in patients with first-episode schizophrenia and builds
upon the one previous in vivo study of NMDAR availability that
used a SPECT tracer in older patients with chronic schizophrenia
(illness duration mean (S.D)= 15.23 (9.21) years) [19]. In keeping
with the present findings, they found a significant reduction in the
DVR of [123I]CNS-1261 in the left hippocampus relative to the
whole brain in medication-free patients (n= 5) compared to
healthy controls. Our study findings are consistent with these, and,
importantly, extend them to first-episode patients, indicating that
alterations in NMDAR availability in the hippocampus are evident
early in the development of the disorder. However, similar to our
study, the SPECT study did not find a difference in NMDAR
availability as measured by the VT in patients relative to healthy
controls, although they did report a global reduction in [123I]CNS-
1261 VT in patients treated with clozapine (n= 9) [20].
Our findings are also consistent with post-mortem data which
provide evidence for lower hippocampal availability of NMDAR in
patients with schizophrenia measured using MK801 binding [37],
and lower hippocampal NR1 mRNA and protein levels in the
hippocampus in schizophrenia patients relative to healthy controls
[38]. As the NR1 subunits are essential components of the NMDAR,
they can be used as a measure of NMDAR number more reliably
than measurements of other subunits [39].
Strengths and limitations
A strength of our study is that the patients were predominantly
antipsychotic-free FEP patients, and the sample size was more
than double that of the SPECT study in chronic patients [19]. One
important consideration is that the VT and DVR do not
differentiate between specific and non-specific binding. As such,
we cannot exclude the possibility that there was an alteration in
non-specific binding contributing to the group differences in DVR.
[18F]GE-179 has nanomolar affinity for the PCP site of the NMDAR
ligand-gated ion channel and low affinity for other CNS receptors,
indicating that its binding is likely to largely reflect NMDAR [40].
However, in vivo studies have been mixed. A study that used a
blocking agent to investigate the specific binding of [18F]GE-179 in
rodents and primates did not find evidence of specificity to
NMDAR [41]. However, this study co-administered anaesthetic
agents which may also alter the availability of the target sites,
complicating interpretation of the findings as tracer binding could
have been altered by anaesthetic agents used in the control group
[41–43]. Notwithstanding this, a recent study found that electrical
stimulation designed to activate NMDAR induced significant
increases in the uptake of [18F]GE-179, and also that the NMDAR
antagonist, ketamine, blocked this increase in uptake, indicating
[18F]GE-179 binds to NMDAR and is sensitive to changes in
NMDAR activity [44]. This provides evidence that the tracer we
used is specific to the NMDAR, and sensitive to manipulations that
activate NMDAR. However, it should be noted that in contrast to
this study, in our study subjects were at rest. Future studies using
activation paradigms or cognitive tasks would be useful to
investigate the impact of receptor activation on specific binding
in patients. There have also been studies in awake animals and
humans using similar arylguanidine-based ligands to the one we
used, such as CNS 5161 [45] and GMOM [46]. These studies have
shown reductions in tracer uptake by NMDAR binding site
antagonists. Using ketamine to block binding to the NMDAR,
Van der Doef et al. reported a reduction in mean [11C]GMOM
inhibitory constant (Ki) of 70% +/−12 in the hippocampus,
indicating specific binding in vivo in the absence of the use of an
NMDAR-modulating anaesthetic [46]. While these studies suggest
that a large proportion of our signal is likely to be specific to the
NMDAR, blocking studies in humans are required to determine
how much of [18F]GE-179 tracer uptake is specific to the NMDAR in
patients. However, this will be challenging because it would
require giving patients a substantial dose of an NMDAR blocker
such as ketamine, which can induce potent psychoactive effects in
patients, which participants may find hard to tolerate while being
scanned.
It is important to recognize that partial volume effects can
potentially contribute to the lower hippocampal DVR values in
patients. However, hippocampal and whole-brain volumes were
not significantly different between the groups, and there was no
correlation between hippocampal DVR and hippocampal volume;
nor did our results change when hippocampal volume was added
into the analysis as a covariate. These analyses suggest that
volume effects are not a major factor in our finding of lower
hippocampal DVR. There were also no significant differences in
cumulative movement between patients and controls, indicating
that partial volume effects or excess movement are unlikely to be
major contributors to the group differences in DVR. It is possible
that our findings were influenced by environmental risk factors for
psychosis as we did not match our groups based on parental
socio-economic status.
Interpretation and implications for understanding the
pathophysiology of psychosis
As DVR is relative to tracer uptake in the brain, it is also possible
that lower hippocampal DVR reflects greater uptake in other brain
regions in schizophrenia. However, if this were the case then VT
values would be higher in other brain regions in schizophrenia,
which was not the case, and there is no consistent post-mortem
evidence of globally increased NMDAR levels in schizophrenia
[18]. Indeed, post-mortem studies in schizophrenia show lower
brain levels of NMDAR in the hippocampus [18], cortex [47–49]
and thalamus [50, 51] relative to controls. Thus, taken together
with post-mortem findings of lower NMDAR levels [37, 38] the
most parsimonious explanation for our findings is that first-
episode patients with schizophrenia have lower hippocampal
NMDAR density compared to healthy volunteers. However, as [18F]
GE-179 binds to the NMDAR intrachannel phencyclidine binding
site when the channel is open, another possibility is that a
reduction in channel opening/receptor activity contributed to our
results [21]. Recently, [18F]GE-179 has shown to have increased















rho = - 0.67, p = 0.0016
Fig. 5 Relationship of tracer uptake in the hippocampus, as
measured by DVR, and depression symptom severity. Dashed line
represents 95% CI.
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uptake following deep brain stimulation (DBS) of the hippocam-
pus, without significant changes in cerebral blood flow, showing
that the tracer is sensitive to a stimulus that leads to NMDAR
activation [40]. Notwithstanding this, in either case the net result
would be lower hippocampal NMDAR signalling, consistent with
hypotheses that there is NMDA hypofunction in schizophrenia,
which would be expected to alter excitation-inhibition balance to
impair hippocampal function [52]. Our findings also add to other
evidence for the involvement of the hippocampus in the
pathophysiology of schizophrenia [53–57].
When we conducted exploratory subgroup analyses, we found
that, there was no significant difference in hippocampal DVR
between antipsychotic-free patients and healthy controls, although
DVR was lower in absolute terms in patients. In contrast, the
antipsychotic-treated patients had significantly lower hippocampal
DVR compared to healthy controls. It should be recognized that
these analyses are exploratory and the study was not designed or
powered to detect differences in subgroups. Nevertheless, this could
suggest either an effect of antipsychotic treatment on NMDAR or
that patient subgroups show differences in NMDAR availability. The
antipsychotics used by our patient group have very low affinities (Ki
>1000 nM) for the tracer’s binding site on the NMDAR (the PCP
binding site: Aripiprazole Ki >4000 nM, Olanzapine Ki >10,000 nM,
Risperidone Ki >10,000 nM) [58] (https://pdsp.unc.edu/databases/
kidb.php). There are no data on the Ki for Lurasidone on NMDAR but
there is evidence that Lurasidone only has a weak affinity for NMDAR
[59] and only one patient was treated with this. Furthermore, there
was no correlation between antipsychotic dose and hippocampal
DVR. Thus, it is unlikely that the results we see are due to the direct
action of the medication on the receptor. All the patients treated
with antipsychotics continued to be symptomatic despite adequate
treatment perhaps suggesting a poor response to dopamine
targeting medications. There is evidence that poor treatment
responders have less significant abnormalities in their dopamine
system and greater glutamate dysfunction [28, 60–62]. Our finding
may, thus, suggest that NMDAR abnormalities are more marked in
patients who show poor response to antipsychotic treatment. It
would be useful to test this in a future study.
There was a negative association between hippocampal DVR
and PANSS total symptoms, in agreement with prior findings in
chronic patients treated with antipsychotic medication [19]. We
found no significant associations with positive or negative
subscales, in contrast to Pilowsky et al. who found a negative
association with negative symptom severity. We cannot exclude
the possibility that there is a weaker relationship with these
symptoms. Nevertheless, this finding indicates that hippocampal
NMDAR alterations may not be directly linked to psychotic
symptoms, consistent with models that these arise from
hyperdopaminergia [5, 63], albeit this may be secondary to
NMDAR dysfunction in the hippocampus [64–67]. Preclinical
models of psychosis suggest that hippocampal NMDAR hypofunc-
tion results in increased glutamatergic activity in pathways that
project from the hippocampus to lead to increased mesostriatal
dopaminergic activity, which is thought to result in psychosis
[68, 69]. Interactions between the NMDAR and serotonin system
may also contribute to psychosis [67].
It is also possible that glutamate dysfunction in other areas
has a greater role in the induction of symptoms. There is
evidence to suggest that glutamate levels in the ACC are
related to greater severity of psychotic symptoms at first
presentation [70]. Furthermore, a recent study found that
thalamic glutamate levels in antipsychotic-naive patients were
significantly negatively correlated with a percent change in
symptoms after antipsychotic treatment [62].
The lack of a strong direct relationship between DVR and
psychotic symptom severity may explain why it has proven
challenging to develop antipsychotic medications targeting the
NMDAR, such as glycine site modulators [71], inhibitors of glycine
reuptake [72], positive allosteric modulation of NMDAR subunits
[73], and other aspects of glutamatergic function for schizophrenia
[73]. We found a significant inverse association between DVR and
the general symptom subscale, which includes items covering
cognitive symptoms. Preclinical studies show hippocampal NMDAR
plays a key role in learning and memory [74, 75]. There is also
evidence that NMDAR blockers, such as ketamine, induce cognitive
impairments in patients with psychosis and healthy controls, and
cognitive impairments are seen in chronic ketamine users [76–79].
Furthermore, there is evidence that patients with schizophrenia
have impairments in cortical plasticity which can be improved with
NMDAR enhancers such as D-serine [80]. These lines of evidence
indicate that lower NMDAR could contribute to cognitive impair-
ments in schizophrenia. However, further work is needed to
determine if lower NMDAR availability is associated with cognitive
impairments. Moreover, our exploratory analysis also demon-
strated an inverse relationship between PANSS depressive
symptom severity and hippocampal VT and DVR of [
18F]GE-179,
extending a prior finding that NMDAR tracer binding was globally
reduced in patients with epilepsy who received treatment for
depression [21], to show a direct association with depressive
symptoms for the first time, as far as we are aware. This finding also
adds to other evidence indicating a role for NMDAR in the
pathophysiology of depressive symptoms, potentially more gen-
erally than just in schizophrenia. However, it is not clear how this
fits with findings that treatment with NMDAR antagonist drugs,
such as esketamine and ketamine, induces rapid antidepressant
effects [81, 82]. A future study in patients with major depressive
disorders would be useful to test this.
Conclusions
Our findings indicate that patients with first-episode psychosis
show lower hippocampal NMDAR availability relative to other
brain regions. This is consistent with patients showing either lower
activity and/or density of NMDAR in the hippocampus relative to
the whole brain; and the hypothesis that NMDA hypofunction in
the hippocampus plays a key role in the pathophysiology of
schizophrenia. Furthermore, we find that lower relative hippo-
campal NMDAR availability is associated with greater total
symptom severity. Further studies are needed to determine the
role of the NMDAR in the development of symptoms.
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